elderly residents of Alberta, Canada which revealed that the hazard ratios for hyperkalaemia and renal dysfunction associated with angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) combination therapy in clinical practice mirror those reported in randomised controlled trials (...
The Valsartan Heart Failure Trial (ValHeft) investigated the benefit of adding valsartan to conventional medical therapy for the management of heart failure.[5]This was the first pivotal trial demonstrating mortality and morbidity reduction when an ARB was added to an ACE inhibitor-based regimen. In...
一项涵盖2436例非小细胞肺癌、晚期胰腺癌、晚期胃癌、浸润性原发性乳腺癌和转移性肾细胞癌患者的七项回顾性观察研究的荟萃分析显示,与单纯化疗相比,ACE抑制剂或血管紧张素受体阻滞剂(ARB)联合标准化疗可改善PFS和OS[OS:HR 0.80(95% CI:0.69-0.92;I2 = 16.4%,P = 0.29);PFS:HR 0.79(95% CI:0.66-0.94;I2...
Combined RAS blockade with ACE inhibitors and ARBs seems to be an efficient treatment option for persons with CHF Stage C and D. However, these individuals are often subject to a multimodal therapy. The addition of an ARB to the existing ACE inhibitor may reduce glomerular filtration pressure, ...
The combination of valsartan and captopril did not reduce the risk of all-cause mortality, CV death, or CV morbidity beyond captopril alone (19). Therefore, ARB is an acceptable alternative to ACE inhibitor in individuals with known stable vascular disease for the prevention of CVD events. ...
多数冠心病患者需要ACEACE抑制剂治疗抑制剂治疗在心肌梗死后患者中,大剂量在心肌梗死后患者中,大剂量ARBARB降低死亡率的效降低死亡率的效果与常规剂量果与常规剂量ACEACE抑制剂相似,但副作用发生率显抑制剂相似,但副作用发生率显著增高著增高在心肌梗死后患者中,在心肌梗死后患者中,ARBARB与与ACEACE抑制剂可能不宜合...
NEJM/JAMA/Lancet三大医学期刊体系这次一起发力阻挡新冠疫情当中给高血压和心血管疾病患者停用ACE抑制剂或者ARB拮抗剂的做法,我表示非常赞赏。新英格兰医学杂志发表文章的链接如下: Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 | NEJMwww.nejm.org ...
BPLTTC主要的组织者、分析者在接受报社采访时强调:对于ARB而言,不是导致更多的心肌梗死事件的发生,而是不能更多的预防心肌梗死的发生 ACC前任主席,著名的Carl Pepine教授,也同样提出了我们治疗高血压的目的,并不仅仅是降低血压本身,同时也要减少高血压不良的预后。 不同的人降压可采取不同的方法,有的人贴硝酸甘油...
These drugs include ARBs, ACEIs and the combination drug valsartan/sacubitril (Entresto) which combines an ARB with a neprilysin inhibitor (also known as an angiotensin receptor-neprilysin inhibitor [ARNI]). Whilst there is evidence that ACEI and ARB treatment may increase expression of ACE-2 ...
This hypothesis is also roo- ted in human and rodent studies showing upregulation of ACE2 mRNA in the heart, kidney, and urine after ACEI/ARB admin- istration13–15. Notably, the effects of ACEI and ARBs on the expression of ACE2 in the respiratory tract have not been pre- viously ...